Coulter lh series hematology analyzer

A total of 314 consecutive patients who underwent FFR measurement for intermediate lesions (40-70% stenosis in quantitative coronary analysis) in the left anterior descending artery from January 2012 to June 2013 were enrolled in this study. Clinical, demographic and angiographic data of the patients were obtained from hospital records. Exclusion criteria were patients with previous myocardial infarction, history of heart failure, severe arrhythmia, anemia according to WHO criteria (hemoglobin value for males <13 g/dl, for females <12 g/dl) [13 (link)], blood transfusion in the last 6 months, acute infection, chronic kidney disease (creatinine clearance <60 ml/min), hematological diseases, malignancy, chronic systemic disease and patients with critical lesions in other coronary arteries and tandem lesions. Based on the exclusion criteria, 68 patients were rejected; the remaining 246 patients formed our study population. Among the participants, 144 had hypertension, and 74 had diabetes mellitus. The study was approved by the Local Ethics Committee. Venous blood samples were taken within 48 h before the FFR measurement for biochemical and hematological measurements including complete blood count, serum creatinine and lipid profile. The RDW levels were determined by a Coulter LH Series hematology analyzer (Beckman Coulter Inc., Hialeah, Fla., USA).